BioLineRx Ltd. (NASDAQ:BLRX) – Equities researchers at Oppenheimer Holdings upped their Q3 2017 earnings estimates for BioLineRx in a note issued to investors on Tuesday. Oppenheimer Holdings analyst M. Breidenbach now anticipates that the biotechnology company will post earnings of ($0.05) per share for the quarter, up from their previous forecast of ($0.06). Oppenheimer Holdings currently has a “Outperform” rating and a $3.00 target price on the stock. Oppenheimer Holdings also issued estimates for BioLineRx’s Q4 2017 earnings at ($0.05) EPS, FY2017 earnings at ($0.23) EPS, Q1 2018 earnings at ($0.05) EPS, FY2018 earnings at ($0.22) EPS, FY2019 earnings at ($0.22) EPS and FY2020 earnings at ($0.07) EPS.

A number of other brokerages also recently issued reports on BLRX. ValuEngine raised BioLineRx from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. Roth Capital started coverage on BioLineRx in a research report on Thursday, August 3rd. They set a “buy” rating and a $3.00 price objective for the company. Zacks Investment Research downgraded BioLineRx from a “buy” rating to a “sell” rating in a research report on Tuesday, June 20th. Maxim Group set a $3.00 price objective on BioLineRx and gave the stock a “buy” rating in a research report on Tuesday. Finally, HC Wainwright set a $4.00 target price on BioLineRx and gave the company a “buy” rating in a report on Saturday, June 3rd. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $2.59.

COPYRIGHT VIOLATION WARNING: This news story was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/08/11/oppenheimer-holdings-comments-on-biolinerx-ltd-s-q3-2017-earnings-blrx.html.

Shares of BioLineRx (BLRX) opened at 1.14 on Friday. The stock’s 50 day moving average is $0.95 and its 200-day moving average is $0.97. BioLineRx has a 52 week low of $0.80 and a 52 week high of $1.42. The stock’s market capitalization is $109.00 million.

BioLineRx (NASDAQ:BLRX) last issued its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.05).

A number of institutional investors have recently made changes to their positions in BLRX. Citadel Advisors LLC boosted its position in shares of BioLineRx by 443.4% in the first quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock worth $102,000 after buying an additional 86,481 shares during the period. Benchmark Capital Advisors boosted its position in shares of BioLineRx by 227.3% in the first quarter. Benchmark Capital Advisors now owns 144,000 shares of the biotechnology company’s stock worth $138,000 after buying an additional 100,000 shares during the period. Renaissance Technologies LLC purchased a new position in shares of BioLineRx during the first quarter worth approximately $126,000. KCG Holdings Inc. boosted its position in shares of BioLineRx by 715.9% in the first quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock worth $168,000 after buying an additional 153,687 shares during the period. Finally, Sabby Management LLC purchased a new position in shares of BioLineRx during the first quarter worth approximately $3,018,000. Institutional investors own 34.91% of the company’s stock.

BioLineRx Company Profile

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.